NCT01246011View on ClinicalTrials.gov

Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion

PHASE4TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions

Coronary Artery Bypass Graft SurgeryPresence of Heparin/Platelet Factor 4 Antibody

Interventions

DRUG

Argatroban and warfarin

Subjects with the presence of heparin PF4 antibodies without signs or symptoms of HIT post CABG will be randomized to receive argatroban and warfarin or no drug for one month.

Trial Locations (1)

02474

Massachusetts General Hospital, Boston